- Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test — Recruiting • Oncology • NCT07883954.
- Sponsor: Mitra Bio.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Background and Study Aims: Melanoma is the most dangerous form of skin cancer, and early detection is crucial for improving patient outcomes. Over 90% of suspected skin cancer lesions are not melanoma, leading to a significant proportion of patients undergoing invasive skin biopsies for non-relevant lesions (1). Mitra Bio has developed a novel, non-invasive skin-tape test that captures skin cells from pigmented lesions that are suspected of being melanoma and detects the presence of melanoma-specific methylation biomarkers. The goal of this study is to further develop and to prospectively clinically…
- : * At least 18 years of age * Undergoing a standard of care biopsy or excision procedure for a pigmented lesion that is suspected of being a melanoma * Willing and able to sign informed consent * Willing to undergo a non-invasive skin tape sample collection procedure prior to standard of care biopsy/excision (up to 1 week prior to or on the day of the biopsy/excision procedure) * Able to complete both the tape collection and biopsy/excision procedures
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.